Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Power of 3D Liver Culture Models for More Predictive and Insightful DMPK Studies

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
LiverChip™ enables robust and reproducible prediction of metabolic clearance in humans and provides extended time course for the study of low clearance compounds.

Zyoxel announces preliminary results from a testing by Sanofi on Zyoxel’s LiverChip™ platform for drug metabolism and pharmacokinetic (DMPK) studies. Sanofi employed a variety of morphological, genetic and functional analyses to fully characterise the LiverChip™ system, the full findings of which will be presented as part of Zyoxel’s In Vitro Liver Technology Symposium taking place on December 10, 2013 in Oxford, UK.

Under the terms of an Equipment Hire Agreement, Sanofi, an integrated global healthcare leader, has been exploring the utility of Zyoxel’s LiverChip™ platform. During the project, which commenced in December 2012 and involved the installation of a LiverChip™ device at a Sanofi research site, the company tested the human hepatocyte LiverChip™ system against current industry gold standard 2D plated cultures of primary hepatocytes. 

Using LiverChip™, Sanofi’s researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChip™ does not suffer from any non-specific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments. 

Extending the duration of cell culture increases pharmaceutical value and relevance 
As Dr. Emma Sceats, Chief Operating Officer of Zyoxel, summarised: “Sanofi have been a very good partner and customer of Zyoxel, and are one of an increasing number of international pharmaceutical companies we are working with. The value proposition of LiverChip’s™ extended time window is proving especially useful for applications such as assessing low clearance compounds, formation and detection of rare metabolites and to study the impact of chronic multiple dosing. We believe that the system can become part of the routine process for pre-clinical drug testing, ensuring only high quality candidates are taken through to clinical trials. Ultimately, we hope this will facilitate the production of more effective medicines that exhibit fewer side effects, enhancing the future treatment of patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!